Switzerland Responds to US Tariffs: Trade Talks and Pharmaceutical Concerns

Swiss Response to US Tariffs

• 🇨🇭 Switzerland was surprised by the US announcement of 39% tariffs on its exports, scheduled to take effect on Thursday.
• 💡 The Swiss government is determined to present a more attractive offer to the US, taking American concerns into account and seeking to ease the tariff situation.
• 🤝 Swiss negotiators have reached out to their US counterparts to find a way forward, aiming for at least a longer timeline than the Thursday deadline.

US Trade Concerns and Swiss Exports

• 💊 A key US concern appears to be lowering drug prices, targeting companies like Novartis and Roche, which have significant profit margins and operations in the US.
• ⚖️ While the 39% tariff exempts pharmaceuticals, there's a broader worry related to the Swiss franc becoming a haven currency as the dollar weakens.
• 📊 Switzerland's trade surplus with the US, partly due to gold exports and also driven by pharmaceuticals, coffee, and watches, is a focal point.

Pharmaceutical Industry Vulnerability

• 🌍 Swiss pharmaceutical companies with substantial US businesses, like Roche (through its subsidiary Genentech), are vulnerable due to Trump's letters to drugmakers worldwide.
• ⚠️ Companies like Novo Nordisk (Danish, but heavily reliant on US revenue from drugs like Ozempic) could be significantly impacted if their products face tariffs or are excluded from Medicaid coverage.
• 📈 The US remains the largest consumer base, making it crucial for these companies to maintain access to the American market.